

Please amend the application as follows:

In the Claims

9 1. (Amended) A method to decrease localized inflammatory responses arising from an ischemia/reperfusion injury in a tissue of a patient comprising intravascularly administering to said patient heparinase enzyme in an effective amount sufficient to decrease neutrophil transmigration through activated endothelium and basement membrane of said vasculature which decreases said localized inflammatory response arising from an ischemia/reperfusion injury.

12 6. (Amended) The method of claim 1, wherein said heparinase enzyme is [overexpressed] expressed from a recombinant nucleotide sequence, in *Flavobacterium heparinum*.

Please add the following new claims.

13 --18. (New) The method of claim 1, wherein said heparinase enzyme is heparinase III.--

--19. (New) The method of claim 1, wherein said ischemia/reperfusion is selected from the group consisting of myocardial infarction, stroke, organ transplant, shock and cardiovascular surgery.--

REMARKS

Claims 1-7 are pending in the application. New claims 18 and 19 have been added. Support for new claim 18 can be found in the specification at least on pages 35-49, and support for new claim 19 can be found at least on page 1. Each of the rejections of the claims shall be addressed below in the order presented in the Office Action. Reconsideration and withdrawal of the rejections to Claims 1-7 in view of the discussion at the interview and the following remarks is respectfully requested.

1. Claim 6 as amended is definite under 35 USC §112, second paragraph.

Claim 6 was rejected as indefinite for recitation of the term "overexpressed". As discussed in the interview, Applicants have amended claim 6 to recite --expressed-- rather than